Patents Represented by Attorney, Agent or Law Firm Jaye P. McLaughlin
-
Patent number: 6653127Abstract: Covalent HCV NS4A-NS3 complexes comprising the central hydrophobic domain of native HCV NS4A peptide, a linker, and the HCV NS3 serine protease domain, wherein the hydrophobic domain of native HCV NS4A peptide is tethered by the linker to the amino terminus of the HCV NS3 protease domain.Type: GrantFiled: October 6, 2000Date of Patent: November 25, 2003Assignee: Schering CorporationInventors: Bruce A. Malcolm, S. Shane Taremi, Patricia C. Weber, Nanhua Yao
-
Patent number: 6610905Abstract: The present invention relates to a non-human transgenic mouse containing a constitutively active G-protein coupled receptor, which produces Kaposi's sarcoma-like symptoms. The transgenic mouse is useful in identification of reagents for the prevention, treatment and/or cure of diseases related to production of proliferative vascular lesions, including Kaposi's sarcoma.Type: GrantFiled: July 19, 2000Date of Patent: August 26, 2003Assignee: Schering CorporationInventors: Sergio A. Lira, Tong-Yuan Yang
-
Patent number: 6531290Abstract: The present invention provides isolated human and bovine TNF-&agr; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&agr;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&agr; convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: October 17, 2001Date of Patent: March 11, 2003Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 6416954Abstract: The present invention relates to the agonist properties of vMIP-I for the chemokine receptor CCR8 as expressed on Th2 cells. Methods of modulating a physiological signal specific to Th2 cells comprising contacting these cells with vMIP-I, agonists and antagonists thereof are disclosed. Methods for treating disease using CCR8 antagonists are also provided. The modulation of the Th2 cell populations through the vMIP-I/CCR8 interaction provides a new means for diagnosing and treating specific disease states and immunologic conditions.Type: GrantFiled: February 3, 2000Date of Patent: July 9, 2002Assignee: Schering CorporationInventor: Joseph A. Hedrick
-
Patent number: 6361939Abstract: Polynucleotides encoding various dendritic cell specific proteins from a primate are provided. Uses of purified sequences are also disclosed, including producing related reagents, e.g., specific antibodies, and purified proteins. Methods of using these reagents and related diagnostic kits are also described.Type: GrantFiled: November 25, 1997Date of Patent: March 26, 2002Assignee: Schering CorporationInventors: Elizabeth Esther Mary Bates, Blandine Marie de Saint-Vis, Christophe Caux, Serge J. E. Lebecque, Jacques Banchereau
-
Patent number: 6211338Abstract: Covalent HCV NS4A-NS3 complexes comprising the central hydrophobic domain of native HCV NS4A peptide, a linker, and the HCV NS3 serine protease domain, wherein the hydrophobic domain of native HCV NS4A peptide is tethered by the linker to the amino terminus of the HCV NS3 protease domain.Type: GrantFiled: November 24, 1998Date of Patent: April 3, 2001Assignee: Schering CorporationInventors: Bruce A. Malcolm, S. Shane Taremi, Patricia C. Weber, Nanhua Yao
-
Patent number: 6004549Abstract: A pharmaceutical composition comprised of a crystalline protein and polyethylene glycol or vegetable oil and a process for producing the same.Type: GrantFiled: December 14, 1994Date of Patent: December 21, 1999Assignee: Schering CorporationInventors: Paul Reichert, Alan W. Hruza, Nagamani Nagabushan, Tattanahalli Nagabhushan
-
Patent number: 5990276Abstract: An inhibitor of the HCV NS3 protease. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the NS4A cofactor. In another embodiment the inhibitor is a bivalent inhibitor comprised of a subsequence, a mutated subsequence or a mutated full-length of a substrate of the NS3 protease linked to a subsequence, a mutated subsequence or a mutated full-length suquence of the HCV NS4A cofactor.Type: GrantFiled: May 9, 1997Date of Patent: November 23, 1999Assignee: Schering CorporationInventors: Rumin Zhang, Philip W. Mui, Patricia C. Weber
-
Patent number: 5908621Abstract: A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.Type: GrantFiled: April 29, 1997Date of Patent: June 1, 1999Assignee: Schering CorporationInventors: Paul Glue, David L. Cutler, Melton B. Affrime
-
Patent number: 5891635Abstract: Hybrid regulatory proteins are provided which contain amino acid sequences that are susceptible to cleavage by specific proteolytic enzymes. When acted upon by such enzymes, the hybrid regulatory proteins are rendered substantially less active, thereby altering the rate of production of products of indicator genes that are controlled by the regulatory proteins. Also provided are DNAs encoding such regulatory proteins, recombinant vectors and transformed eukaryotic cells containing such DNAs, and methods for identifying inhibitors of the specific proteolytic enzymes.Type: GrantFiled: July 23, 1997Date of Patent: April 6, 1999Assignee: Schering CorporationInventor: Bimalendu Dasmahapatra
-
Patent number: 5853977Abstract: The present invention provides isolated human and bovine TNF-.alpha. convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-.alpha.. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-.alpha. convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: July 10, 1997Date of Patent: December 29, 1998Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 5843752Abstract: Soluble covalent HCV NS3-NS4A complexes comprising the catalytic domain of native HICV NS3 protease fused to an HCV NS4A cofactor, wherein the cofactor has been modified to prevent cleavage by the HCV NS3 protease.Type: GrantFiled: May 12, 1995Date of Patent: December 1, 1998Assignee: Schering CorporationInventors: Bimalendu Dasmahapatra, Nancy J. Butkiewicz
-
Patent number: 5767233Abstract: Soluble HCV nonstructural substrates of the HCV polyprotein.Type: GrantFiled: May 12, 1995Date of Patent: June 16, 1998Assignee: Schering CorporationInventors: Rumin Zhang, Michael G. Murray, Lata Ramanathan
-
Patent number: 5759795Abstract: This invention provides materials and methods for identifying inhibitors of a Hepatitis C Virus NS3 protein ATPase. Methods for making and purifying such an ATPase are also provided by this invention.Type: GrantFiled: March 8, 1996Date of Patent: June 2, 1998Assignee: Schering CorporationInventor: Ronald G. Jubin
-
Patent number: 5741485Abstract: A method for making crystals of zinc interferon alpha-2, and the use thereof in depot formulations, are disclosed.Type: GrantFiled: June 6, 1995Date of Patent: April 21, 1998Assignee: Schering CorporationInventors: Paul Reichert, Gerald S. Hammond, Hung V. Le, Tattanahalli L. Nagabhushan, Paul P. Trotta
-
Patent number: 5714371Abstract: A method for solubulizing and refolding insoluble aggregates of HCV protease is presented. Insoluble aggregates of HCV NS3 protease are extracted from bacteria producing the aggregates. The aggregates of HCV NS3 are then solubilized in a buffer containing the denaturing reagent. Solubilized protease is then placed in an acidic buffer containing a reducing agent. The denaturing reagent is then removed from the buffer under acidic conditions. The pH of the buffer containing HCV NS3 protease is then raised in a step-wise manner to a pH of about 7-8 so as to produce properly refolded soluble, active HCV NS3 protease.Type: GrantFiled: December 13, 1995Date of Patent: February 3, 1998Assignee: Schering CorporationInventors: Lata Ramanathan, Michele Wendel
-
Patent number: 5710251Abstract: Disclosed is a method for purifying Interleukin-10 (IL-10). The method is comprised of subjecting an IL-10 containing solution to cation exchange chromatography, anion exchange chromatography, hydroxyapatite chromatography, and gel filtration chromatography. The present invention is also comprised of a process for separating different IL-10 dimers present in a protein fraction from each other by subjecting the protein fraction to hydroxyapatite chromatography. The present invention is also comprised of a process for separating variants of a protein differing in an N-terminal amino acid sequence present in a protein fraction from each other by subjecting the protein fraction to hydroxyapatite chromatography.Type: GrantFiled: December 18, 1995Date of Patent: January 20, 1998Assignee: Schering CorporationInventors: Gary Vellekamp, Susan Cannon-Carlson, John Tang